Skip to content
2000
Volume 25, Issue 18
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

A neurohormone with strong central nervous system activity, melatonin plays a role in regulating circadian rhythms. It affects practically all tissues and organs and has a broad functional repertoire. It is primarily employed as a dietary supplement; melatonin aids in sleep regulation and the re-establishment of arousal cycles. Despite having very low toxicity, melatonin's tissue availability is constrained by pharmacokinetic problems such as poor oral bioavailability and a brief half-life. The synthesis and medicinal applications of melatonin and its derivatives are the main focus of this review study. Melatonin is considered as a beneficial agent suitable for safely treating and preventing various health conditions. This review covers synthesis approaches and pharmacological applications of melatonin and its derivatives published from the 1990s to 2024. The latest development in several studies involves the concurrent administration of melatonin with other drugs to enhance therapeutic effectiveness and mitigate adverse effects. Hybrid ligands, such as melatonin-tamoxifen and melatonin-tacrine derivatives are combined to give distinct effects. This review highlights the importance of continued research into melatonin and its derivatives, paving the way for developing novel and more potent therapeutic agents.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ctmc/10.2174/0115680266331681250130072302
2025-02-06
2026-02-26

  • From This Site

    /content/journals/ctmc/10.2174/0115680266331681250130072302
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. JaworekJ. Leja-SzpakA. Nawrot-PorąbkaK. SzklarczykJ. KotM. PierzchalskiP. GóralskaM. CeranowiczP. WarzechaZ. DembinskiA. BoniorJ. Effects of melatonin and its analogues on pancreatic inflammation, enzyme secretion, and tumorigenesis.Int. J. Mol. Sci.2017185101410.3390/ijms1805101428481310
     [Google Scholar]
  2. ReiterR.J. TanD.X. Rosales-CorralS. ManchesterL.C. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives.Mini Rev. Med. Chem.201313337338410.2174/138955751131303000623190034
     [Google Scholar]
  3. ArnaoM.B. Giraldo-AcostaM. Castejón-CastillejoA. Losada-LoránM. Sánchez-HerreríasP. El MihyaouiA. CanoA. Hernández-RuizJ. Melatonin from microorganisms, algae, and plants as possible alternatives to synthetic melatonin.Metabolites20231317210.3390/metabo1301007236676997
     [Google Scholar]
  4. NehmeP.A. AmaralF. LowdenA. SkeneD.J. Cipolla-NetoJ. MorenoC.R.C. Reduced melatonin synthesis in pregnant night workers: Metabolic implications for offspring.Med. Hypotheses201913210935310.1016/j.mehy.2019.10935331421432
     [Google Scholar]
  5. RenW. YinJ. XiaoH. ChenS. LiuG. TanB. LiN. PengY. LiT. ZengB. LiW. WeiH. YinZ. WuG. HardwidgeP.R. YinY. Intestinal microbiota-derived GABA mediates interleukin-17 expression during enterotoxigenic Escherichia coli infection.Front. Immunol.2017768510.3389/fimmu.2016.0068528138329
     [Google Scholar]
  6. YinJ. LiY. HanH. MaJ. LiuG. WuX. HuangX. FangR. BabaK. BinP. ZhuG. RenW. TanB. TosiniG. HeX. LiT. YinY. Administration of exogenous melatonin improves the diurnal rhythms of the gut microbiota in mice fed a high-fat diet.mSystems20205310.1128/msystems.00002-2010.1128/msystems.00002‑2032430404
     [Google Scholar]
  7. TuliH.S. KashyapD. SharmaA.K. SandhuS.S. Molecular aspects of melatonin (MLT)-mediated therapeutic effects.Life Sci.201513514715710.1016/j.lfs.2015.06.00426135621
     [Google Scholar]
  8. AnisimovV.N. PopovichI.G. ZabezhinskiM.A. AnisimovS.V. VesnushkinG.M. VinogradovaI.A. Melatonin as antioxidant, geroprotector and anticarcinogen.Biochim. Biophys. Acta Bioenerg.200617575-657358910.1016/j.bbabio.2006.03.01216678784
     [Google Scholar]
  9. Benítez-KingG. Melatonin as a cytoskeletal modulator: Implications for cell physiology and disease.J. Pineal Res.20064011910.1111/j.1600‑079X.2005.00282.x16313492
     [Google Scholar]
  10. ClaustratB. Le BarsD. BrunJ. ThivolleP. MalloC. ArendtJ. ChazotG. Plasma and brain pharmacokinetic studies in humans after intravenous administration of cold or 11C labeled melatonin.Adv. Pineal Res.19893305310
     [Google Scholar]
  11. LeeP.P.N. PangS.F. Identification and characterization of melatonin binding sites in the gastrointestinal tract of ducks.Life Sci.199250211712510.1016/0024‑3205(92)90293‑X1731167
     [Google Scholar]
  12. ReillyT. The body clock and athletic performance.Biol. Rhythm Res.2009401374410.1080/09291010802067015
     [Google Scholar]
  13. ManfrediniR. ManfrediniF. FersiniC. ConconiF. Circadian rhythms, athletic performance, and jet lag.Br. J. Sports Med.199832210110610.1136/bjsm.32.2.1019631214
     [Google Scholar]
  14. RivaraS. PalaD. BediniA. SpadoniG. Therapeutic uses of melatonin and melatonin derivatives: A patent review (2012 – 2014).Expert Opin. Ther. Pat.201525442544110.1517/13543776.2014.100173925579320
     [Google Scholar]
  15. LemoineP. ZisapelN. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia.Expert Opin. Pharmacother.201213689590510.1517/14656566.2012.66707622429105
     [Google Scholar]
  16. ZlotosD.P. JockersR. CeconE. RivaraS. Witt-EnderbyP.A. MT1 and MT2 melatonin receptors: Ligands, models, oligomers, and therapeutic potential.J. Med. Chem.20145783161318510.1021/jm401343c24228714
     [Google Scholar]
  17. LeclercV. EttaoussiM. RamiM. FarceA. BoutinJ.A. DelagrangeP. CaignardD.H. RenardP. BerthelotP. YousS. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.Eur. J. Med. Chem.20114651622162910.1016/j.ejmech.2011.02.01021377769
     [Google Scholar]
  18. Pandi-PerumalS.R. SrinivasanV. MaestroniG.J.M. CardinaliD.P. PoeggelerB. HardelandR. Melatonin.FEBS J.2006273132813283810.1111/j.1742‑4658.2006.05322.x16817850
     [Google Scholar]
  19. NosjeanO. FerroM. CogéF. BeauvergerP. HenlinJ.M. LefoulonF. FauchèreJ.L. DelagrangeP. CanetE. BoutinJ.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2.J. Biol. Chem.200027540313113131710.1074/jbc.M00514120010913150
     [Google Scholar]
  20. SpadoniG. BediniA. RivaraS. MorM. Melatonin receptor agonists: New options for insomnia and depression treatment.CNS Neurosci. Ther.201117673374110.1111/j.1755‑5949.2010.00197.x21554566
     [Google Scholar]
  21. ZemlanF.P. MulchaheyJ.J. ScharfM.B. MaylebenD.W. RosenbergR. LankfordA. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial.J. Clin. Psychiatry200566338439010.4088/JCP.v66n031615766306
     [Google Scholar]
  22. AndradeC. SrihariB.S. ReddyK.P. ChandrammaL. Melatonin in medically ill patients with insomnia: A double-blind, placebo-controlled study.J. Clin. Psychiatry2001621414510.4088/JCP.v62n010911235927
     [Google Scholar]
  23. SrinivasanV CardinaliDP Pandi PerumalSR BrownGM Melatonin agonists for treatment of sleep and depressive disorders.J. Exp. Integr. Med.20111314915810.5455/jeim.100511.ir.005
     [Google Scholar]
  24. Guardiola-LemaitreB. Melatoninergic receptor agonists and antagonists: Pharmacological aspects and therapeutic perspective.Ann. Pharm. Fr.200563638540010.1016/S0003‑4509(05)82308‑916292232
     [Google Scholar]
  25. CardellM. JungF.J. ZhaiW. HillingerS. WelpA. ManzB. WederW. KoromS. Acute allograft rejection and immunosuppression: Influence on endogenous melatonin secretion.J. Pineal Res.200844326126610.1111/j.1600‑079X.2007.00521.x18339121
     [Google Scholar]
  26. SamantarayS. SribnickE.A. DasA. KnaryanV.H. MatzelleD.D. YallapragadaA.V. ReiterR.J. RayS.K. BanikN.L. Melatonin attenuates calpain upregulation, axonal damage and neuronal death in spinal cord injury in rats.J. Pineal Res.200844434835710.1111/j.1600‑079X.2007.00534.x18086148
     [Google Scholar]
  27. KonturekP.C. KonturekS.J. BurnatG. BrzozowskiT. BrzozowskaI. ReiterR.J. Dynamic physiological and molecular changes in gastric ulcer healing achieved by melatonin and its precursor L ‐tryptophan in rats.J. Pineal Res.200845218019010.1111/j.1600‑079X.2008.00574.x18298459
     [Google Scholar]
  28. LinC.H. HuangJ.Y. ChingC.H. ChuangJ.I. Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats.J. Pineal Res.200844220521310.1111/j.1600‑079X.2007.00510.x18289173
     [Google Scholar]
  29. TengattiniS. ReiterR.J. TanD.X. TerronM.P. RodellaL.F. RezzaniR. Cardiovascular diseases: Protective effects of melatonin.J. Pineal Res.2008441162510.1111/j.1600‑079X.2007.00518.x18078444
     [Google Scholar]
  30. ClaustratB. BrunJ. ChazotG. The basic physiology and pathophysiology of melatonin.Sleep Med. Rev.200591112410.1016/j.smrv.2004.08.00115649735
     [Google Scholar]
  31. NowakJ.Z. ZawilskaJ.B. Melatonin and its physiological and therapeutic properties.Pharm. World Sci.1998201182710.1023/A:10086887240589536467
     [Google Scholar]
  32. HerxheimerA. PetrieK.J. Cochrane Common Mental Disorders Group Melatonin for the prevention and treatment of jet lag.Cochrane Libr.200220101CD00152010.1002/14651858.CD00152012076414
     [Google Scholar]
  33. TurekF. GilletteM. Melatonin, sleep, and circadian rhythms: Rationale for development of specific melatonin agonists.Sleep Med.20045652353210.1016/j.sleep.2004.07.00915511698
     [Google Scholar]
  34. Schutte-RodinS. BrochL. BuysseD. DorseyC. SateiaM. Clinical guideline for the evaluation and management of chronic insomnia in adults.J. Clin. Sleep Med.20084548750410.5664/jcsm.2728618853708
     [Google Scholar]
  35. TaylorD.J. MalloryL.J. LichsteinK.L. DurrenceH.H. RiedelB.W. BushA.J. Comorbidity of chronic insomnia with medical problems.Sleep200730221321810.1093/sleep/30.2.21317326547
     [Google Scholar]
  36. MaurerL.F. EspieC.A. KyleS.D. How does sleep restriction therapy for insomnia work? A systematic review of mechanistic evidence and the introduction of the Triple-R model.Sleep Med. Rev.20184212713810.1016/j.smrv.2018.07.00530177248
     [Google Scholar]
  37. PhamL. BaiocchiL. KennedyL. SatoK. MeadowsV. MengF. HuangC.K. KunduD. ZhouT. ChenL. AlpiniG. FrancisH. The interplay between mast cells, pineal gland, and circadian rhythm: Links between histamine, melatonin, and inflammatory mediators.J. Pineal Res.2021702e1269910.1111/jpi.1269933020940
     [Google Scholar]
  38. FergusonS.A. RajaratnamS.M.W. DawsonD. Melatonin agonists and insomnia.Expert Rev. Neurother.201010230531810.1586/ern.10.120136385
     [Google Scholar]
  39. SpielmanA.J. CarusoL.S. GlovinskyP.B. A behavioral perspective on insomnia treatment.Psychiatr. Clin. North Am.198710454155310.1016/S0193‑953X(18)30532‑X3332317
     [Google Scholar]
  40. FitzgeraldL.R. ReedJ.E. Melatonin agonists for the treatment of sleep disorders and major depression.Annu. Rep. Med. Chem.200439253710.1016/S0065‑7743(04)39003‑2
     [Google Scholar]
  41. BazanL RothT DrakeCL Management of InsomniaEssentials of Sleep Medicine: An Approach for Clinical Pulmonology.Humana Press201224927610.1007/978‑1‑60761‑735‑8_14
     [Google Scholar]
  42. SuttonD.A. MoldofskyH. BadleyE.M. Insomnia and health problems in Canadians.Sleep200124666567010.1093/sleep/24.6.66511560179
     [Google Scholar]
  43. AernoutE. BenradiaI. HazoJ.B. SyA. Askevis-LeherpeuxF. SebbaneD. RoelandtJ.L. International study of the prevalence and factors associated with insomnia in the general population.Sleep Med.20218218619210.1016/j.sleep.2021.03.02833957414
     [Google Scholar]
  44. Cruz-SanabriaF. CarmassiC. BrunoS. BazzaniA. CarliM. ScarselliM. FaragunaU. Melatonin as a chronobiotic with sleep-promoting properties.Curr. Neuropharmacol.202321495198710.2174/1570159X2066622021715261735176989
     [Google Scholar]
  45. Sánchez-BarcelóE.J. MediavillaM.D. TanD.X. ReiterR.J. Clinical uses of melatonin: Evaluation of human trials.Curr. Med. Chem.201017192070209510.2174/09298671079123368920423309
     [Google Scholar]
  46. TeaimaM. YasserM. ElfarN. ShoueirK. El-NabarawiM. HelalD. Construction of sublingual trilaminated Eszopiclone fast dissolving film for the treatment of Insomnia: Formulation, characterization and In vivo clinical comparative pharmacokinetic study in healthy human subjects.PLoS One2022176e026601910.1371/journal.pone.026601935679274
     [Google Scholar]
  47. SrinivasanV. BrzezinskiA. OterS. ShillcuttS.D. , Eds.; Melatonin and melatonergic drugs in clinical practice.Springer India201410.1007/978‑81‑322‑0825‑9
     [Google Scholar]
  48. MorM. RivaraS. PalaD. BediniA. SpadoniG. TarziaG. Recent advances in the development of melatonin MT 1 and MT 2 receptor agonists.Expert Opin. Ther. Pat.20102081059107710.1517/13543776.2010.49645520533893
     [Google Scholar]
  49. CardinaliD.P. SrinivasanV. BrzezinskiA. BrownG.M. Melatonin and its analogs in insomnia and depression.J. Pineal Res.201252436537510.1111/j.1600‑079X.2011.00962.x21951153
     [Google Scholar]
  50. CorneliusJ.R. PittockS.J. McKeonA. LennonV.A. AstonP.A. JosephsK.A. Tippmann-PeikertM. SilberM.H. Sleep manifestations of voltage-gated potassium channel complex autoimmunity.Arch. Neurol.201168673373810.1001/archneurol.2011.10621670396
     [Google Scholar]
  51. ZhdanovaI.V. Advances in the management of insomnia.Expert Opin. Pharmacother.2004571573157910.1517/14656566.5.7.157315212607
     [Google Scholar]
  52. KellerR.M. Formulation and method to induce a deep state of relaxation.Patent US 9,040,582,2015
  53. LiuJ. CloughS.J. HutchinsonA.J. Adamah-BiassiE.B. Popovska-GorevskiM. DubocovichM.L. MT1 and MT2 melatonin receptors: A therapeutic perspective.Annu. Rev. Pharmacol. Toxicol.201656136138310.1146/annurev‑pharmtox‑010814‑12474226514204
     [Google Scholar]
  54. ShochatT. LuboshitzkyR. LavieP. Nocturnal melatonin onset is phase locked to the primary sleep gate.Am. J. Physiol. Regul. Integr. Comp. Physiol.19972731R364R37010.1152/ajpregu.1997.273.1.R3649249573
     [Google Scholar]
  55. XieZ. ChenF. LiW.A. GengX. LiC. MengX. FengY. LiuW. YuF. A review of sleep disorders and melatonin.Neurol. Res.201739655956510.1080/01616412.2017.131586428460563
     [Google Scholar]
  56. Pandi-PerumalS.R. SrinivasanV. PoeggelerB. HardelandR. CardinaliD.P. Drug insight: The use of melatonergic agonists for the treatment of insomnia—focus on ramelteon.Nat. Clin. Pract. Neurol.20073422122810.1038/ncpneuro046717410109
     [Google Scholar]
  57. WulffK. GattiS. WettsteinJ.G. FosterR.G. Sleep and circadian rhythm disruption in psychiatric and neurodegenerative disease.Nat. Rev. Neurosci.201011858959910.1038/nrn286820631712
     [Google Scholar]
  58. RaczA. KovacsP. VargaC. Pharmaceutical compositions for the treatment of depression or symptoms suggesting depression.Patent US 10/297,280,2004
  59. CenterN. BymasterF. BrownsburgI.N. PiskorskiW. Patent Application Publication.Patent US 2021/0161863 A1,
  60. JobesD.A. GregorianM.J. ColbornV.A. A stepped care approach to clinical suicide prevention.Psychol. Serv.201815324325010.1037/ser000022930080081
     [Google Scholar]
  61. TangN.K.Y. GoodchildC.E. SalkovskisP.M. Hybrid cognitive-behaviour therapy for individuals with insomnia and chronic pain: A pilot randomised controlled trial.Behav. Res. Ther.2012501281482110.1016/j.brat.2012.08.00623123531
     [Google Scholar]
  62. WilhelmsenM. AmirianI. ReiterR.J. RosenbergJ. GögenurI. Analgesic effects of melatonin: A review of current evidence from experimental and clinical studies.J. Pineal Res.201151327027710.1111/j.1600‑079X.2011.00895.x21615490
     [Google Scholar]
  63. GagnierJ.J. The therapeutic potential of melatonin in migraines and other headache types.Altern. Med. Rev.20016438338911578254
     [Google Scholar]
  64. CiteraG. AriasM.A. Maldonado-CoccoJ.A. La´zaroM.A. RosemffetM.G. BruscoL.I. ScheinesE.J. CardinalliD.P. The effect of melatonin in patients with fibromyalgia: A pilot study.Clin. Rheumatol.200019191310.1007/s10067005000310752492
     [Google Scholar]
  65. DanilovA. KurganovaJ. Melatonin in chronic pain syndromes.Pain Ther.20165111710.1007/s40122‑016‑0049‑y26984272
     [Google Scholar]
  66. CuestaM. BoudreauP. Dubeau-LaraméeG. CermakianN. BoivinD.B. Simulated night shift disrupts circadian rhythms of immune functions in humans.J. Immunol.201619662466247510.4049/jimmunol.150242226873990
     [Google Scholar]
  67. Sánchez-BarcelóE.J. CosS. MediavillaD. Martínez-CampaC. GonzálezA. Alonso-GonzálezC. Melatonin–estrogen interactions in breast cancer.J. Pineal Res.200538421722210.1111/j.1600‑079X.2004.00207.x15813897
     [Google Scholar]
  68. BizzarriM. ProiettiS. CucinaA. ReiterR.J. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: A review.Expert Opin. Ther. Targets201317121483149610.1517/14728222.2013.83489024032643
     [Google Scholar]
  69. TamC.W. MoC.W. YaoK.M. ShiuS.Y.W. Signaling mechanisms of melatonin in antiproliferation of hormone‐refractory 22Rv1 human prostate cancer cells: implications for prostate cancer chemoprevention.J. Pineal Res.200742219120210.1111/j.1600‑079X.2006.00406.x17286752
     [Google Scholar]
  70. ShiuS.Y.W. PangB. TamC.W. YaoK.M. Signal transduction of receptor-mediated antiproliferative action of melatonin on human prostate epithelial cells involves dual activation of Gαs and Gαq proteins.J. Pineal Res.201049330131110.1111/j.1600‑079X.2010.00795.x20695976
     [Google Scholar]
  71. GocekE. StudzinskiG.P. DNA repair in despair—Vitamin D is not fair.J. Cell. Biochem.201611781733174410.1002/jcb.2555227122067
     [Google Scholar]
  72. KimM. MirandolaL. PandeyA. NguyenD.D. JenkinsM.R. TurcelM. CobosE. Chiriva-InternatiM. Application of vitamin D and derivatives in hematological malignancies.Cancer Lett.2012319182210.1016/j.canlet.2011.10.02622193723
     [Google Scholar]
  73. EkmekciogluC. Expression and putative functions of melatonin receptors in malignant cells and tissues.Wien. Med. Wochenschr.201416421-2247247810.1007/s10354‑014‑0289‑625023005
     [Google Scholar]
  74. JiangZ.G. NelsonC.S. AllenC.N. Melatonin activates an outward current and inhibits Ih in rat suprachiasmatic nucleus neurons.Brain Res.19956871-212513210.1016/0006‑8993(95)00478‑97583297
     [Google Scholar]
  75. GrantS.G. MelanM.A. LatimerJ.J. Witt-EnderbyP.A. Melatonin and breast cancer: Cellular mechanisms, clinical studies and future perspectives.Expert Rev. Mol. Med.200911e510.1017/S146239940900098219193248
     [Google Scholar]
  76. Sanchez-BarceloE.J. MediavillaM.D. Alonso-GonzalezC. ReiterR.J. Melatonin uses in oncology: Breast cancer prevention and reduction of the side effects of chemotherapy and radiation.Expert Opin. Investig. Drugs201221681983110.1517/13543784.2012.68104522500582
     [Google Scholar]
  77. BlaskD.E. DauchyR.T. DauchyE.M. MaoL. HillS.M. GreeneM.W. BelancioV.P. SauerL.A. DavidsonL. Light exposure at night disrupts host/cancer circadian regulatory dynamics: impact on the Warburg effect, lipid signaling and tumor growth prevention.PLoS One201498e10277610.1371/journal.pone.010277625099274
     [Google Scholar]
  78. Witt-EnderbyP.A. DavisV.L. Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer.Patent US 8,618,083,2013
  79. ClemensJ.A. FlaughM.E. Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma.Patent US 5,196,435,1993
  80. Witt-EnderbyP.A. DavisV.L. LapinskyD. Holy Spirit, assignee. Anti-cancer tamoxifen-melatonin hybrid ligand.Patent US 8,785,501,2014
  81. YangD.J. WallaceS. High affinity tamoxifen derivatives and uses thereof.Patent US 5,192,525,1993
  82. ZhangX. LuH. WangY. LiuC. ZhuW. ZhengS. WanF. Taurine induces the apoptosis of breast cancer cells by regulating apoptosis-related proteins of mitochondria.Int. J. Mol. Med.201535121822610.3892/ijmm.2014.200225395275
     [Google Scholar]
  83. StubbeC.E. ValeroM. Complementary strategies for the management of radiation therapy side effects.J. Adv. Pract. Oncol.20134421923110.6004/jadpro.2013.4.4.325032003
     [Google Scholar]
  84. Sedighi PashakiA. MohammadianK. AfsharS. GholamiM.H. MoradiA. JavadiniaS.A. Keshtpour AmlashiZ. A randomized, controlled, parallel-group, trial on the effects of melatonin on fatigue associated with breast cancer and its adjuvant treatments.Integr. Cancer Ther.202120153473542098834310.1177/153473542098834333543655
     [Google Scholar]
  85. ReinertsenK.V. CvancarovaM. LogeJ.H. EdvardsenH. WistE. FossåS.D. Predictors and course of chronic fatigue in long-term breast cancer survivors.J. Cancer Surviv.20104440541410.1007/s11764‑010‑0145‑720862614
     [Google Scholar]
  86. HansenM.V. MadsenM.T. HagemanI. RasmussenL.S. BokmandS. RosenbergJ. GögenurI. The effect of MELatOnin on Depression, anxietY, cognitive function and sleep disturbances in patients with breast cancer. The MELODY trial: Protocol for a randomised, placebo-controlled, double-blinded trial.BMJ Open201221e00064710.1136/bmjopen‑2011‑00064722240653
     [Google Scholar]
  87. SinghM. JadhavH.R. Melatonin: Functions and ligands.Drug Discov. Today20141991410141810.1016/j.drudis.2014.04.01424792719
     [Google Scholar]
  88. Acuña-CastroviejoD. EscamesG. VenegasC. Díaz-CasadoM.E. Lima-CabelloE. LópezL.C. Rosales-CorralS. TanD.X. ReiterR.J. Extrapineal melatonin: Sources, regulation, and potential functions.Cell. Mol. Life Sci.201471162997302510.1007/s00018‑014‑1579‑224554058
     [Google Scholar]
  89. SlominskiA. KleszczyńskiK. SemakI. JanjetovicZ. ŻmijewskiM. KimT.K. SlominskiR. ReiterR. FischerT. Local melatoninergic system as the protector of skin integrity.Int. J. Mol. Sci.20141510177051773210.3390/ijms15101770525272227
     [Google Scholar]
  90. GaudetS.J. SlominskiA. EtminanM. PruskiD. PausR. NamboodiriM A A. Identification and characterization of two isozymic forms of arylamine N-acetyltransferase in Syrian hamster skin.J. Invest. Dermatol.1993101566066510.1111/1523‑1747.ep123716728228325
     [Google Scholar]
  91. RosaG.E. CastroviejoD.A. Composition comprising melatonin or its derivatives with coenzyme Q10 and use thereof against ageing of the skin.Patent US 10,092,544,2018
  92. García-CorzoL. Luna-SánchezM. DoerrierC. GarcíaJ.A. GuarásA. Acín-PérezR. Bullejos-PeregrínJ. LópezA. EscamesG. EnríquezJ.A. Acuña-CastroviejoD. LópezL.C. Dysfunctional Coq9 protein causes predominant encephalomyopathy associated with CoQ deficiency.Hum. Mol. Genet.20132261233124810.1093/hmg/dds53023255162
     [Google Scholar]
  93. MorgantiP. Melatonin and immunostimulating substance-based compositions.Patent US 8,802,117,2014
  94. MorgantiP. BrunoC. GuarneriF. CardilloA. Del CiottoP. ValenzanoF. Role of topical and nutritional supplement to modify the oxidative stress *.Int. J. Cosmet. Sci.200224633133910.1046/j.1467‑2494.2002.00159.x18494887
     [Google Scholar]
  95. TalibW.H. AlsayedA.R. AbuawadA. DaoudS. MahmodA.I. Melatonin in cancer treatment: Current knowledge and future opportunities.Molecules2021269250610.3390/molecules2609250633923028
     [Google Scholar]
  96. EndriciG. Melatonin and an antimicrobial or antibacterial agent for the treatment of acne.Patent US 13/978,742,2014
  97. BénèsL. ClaustratB. HorrièreF. GeoffriauM. KonsilJ. ParrottK.A. DeGrandeG. McQuinnR.L. AyresJ.W. Transmucosal, oral controlled-release, and transdermal drug administration in human subjects: A crossover study with melatonin.J. Pharm. Sci.199786101115111910.1021/js970011z9344167
     [Google Scholar]
  98. PlakogiannisF.M. ModiN. Transdermal micro-dosing delivery of pharmaceutical agentsPatent US 17/879,846,2023
  99. LuchettiF. CanonicoB. BartoliniD. ArcangelettiM. CiffolilliS. MurdoloG. PiroddiM. PapaS. ReiterR.J. GalliF. Melatonin regulates mesenchymal stem cell differentiation: A review.J. Pineal Res.201456438239710.1111/jpi.1213324650016
     [Google Scholar]
  100. SlominskiR.M. ReiterR.J. Schlabritz-LoutsevitchN. OstromR.S. SlominskiA.T. Melatonin membrane receptors in peripheral tissues: Distribution and functions.Mol. Cell. Endocrinol.2012351215216610.1016/j.mce.2012.01.00422245784
     [Google Scholar]
  101. EkmekciogluC. Melatonin receptors in humans: Biological role and clinical relevance.Biomed. Pharmacother.20066039710810.1016/j.biopha.2006.01.00216527442
     [Google Scholar]
  102. Witt-EnderbyP.A. RadioN.M. DoctorJ.S. DavisV.L. Therapeutic treatments potentially mediated by melatonin receptors: Potential clinical uses in the prevention of osteoporosis, cancer and as an adjuvant therapy.J. Pineal Res.200641429730510.1111/j.1600‑079X.2006.00369.x17014686
     [Google Scholar]
  103. YiallourisA. TsioutisC. AgapidakiE. ZafeiriM. AgouridisA.P. NtourakisD. JohnsonE.O. Adrenal aging and its implications on stress responsiveness in humans.Front. Endocrinol.2019105410.3389/fendo.2019.0005430792695
     [Google Scholar]
  104. LinH. SohnJ. ShenH. LanghansM.T. TuanR.S. Bone marrow mesenchymal stem cells: Aging and tissue engineering applications to enhance bone healing.Biomaterials20192039611010.1016/j.biomaterials.2018.06.02629980291
     [Google Scholar]
  105. RutkowskiJ.L. Formulations and methods for recovery from dental surgery.Patent US 8,124,130,2012
  106. HelfrichM.H. Bone research protocols. RalstonS.H. Humana Press200310.1385/1592593666
     [Google Scholar]
  107. TurnbullG. ClarkeJ. PicardF. RichesP. JiaL. HanF. LiB. ShuW. 3D bioactive composite scaffolds for bone tissue engineering.Bioact. Mater.20183327831410.1016/j.bioactmat.2017.10.00129744467
     [Google Scholar]
  108. KoushikT.M. MillerC.M. AntunesE. Bone tissue engineering scaffolds: Function of multi‐material hierarchically structured scaffolds.Adv. Healthc. Mater.2023129220276610.1002/adhm.20220276636512599
     [Google Scholar]
  109. HuangJ. LiY. HeC. Melatonin having therapeutic bone regenerating capacity in biomaterials.Curr. Pharm. Biotechnol.202223570771810.2174/138920102266621070914534734250874
     [Google Scholar]
  110. RivaraS. MorM. BediniA. SpadoniG. TarziaG. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders.Curr. Top. Med. Chem.200881195496810.2174/15680260878493671918673165
     [Google Scholar]
  111. O'Neal-MoffittG. Role of MT1/MT2 melatonin membrane receptors in mediating the neuroprotective effects of melatonin in Alzheimer's disease.Available from: https://repository.lib.fsu.edu/islandora/object/fsu:254487
  112. KasaharaT. AbeK. MekadaK. YoshikiA. KatoT. Genetic variation of melatonin productivity in laboratory mice under domestication.Proc. Natl. Acad. Sci. USA2010107146412641710.1073/pnas.091439910720308563
     [Google Scholar]
  113. PechanovaO. PaulisL. SimkoF. Peripheral and central effects of melatonin on blood pressure regulation.Int. J. Mol. Sci.20141510179201793710.3390/ijms15101792025299692
     [Google Scholar]
  114. SimkoF. PechanovaO. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment.J. Pineal Res.200947212713310.1111/j.1600‑079X.2009.00697.x19570132
     [Google Scholar]
  115. GuzikP. WykretowiczA. KrauzeT. PiskorskiJ. AdamskaK. MilewskaA. WesselingK.H. WysockiH. Add-on therapy with a nighttime dose of doxazosin in patients with uncontrolled hypertension: Effects on autonomic modulation of the cardiovascular system.Hypertens. Res.200831344345310.1291/hypres.31.44318497463
     [Google Scholar]
  116. LaudonM. Grossman ZisapelN. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials.Vasc. Health Risk Manag.2011757758410.2147/VHRM.S2460321966222
     [Google Scholar]
  117. ZisapelN. LaudonM. Method and formulation for treating resistance to antihypertensives and related conditions.Patent US 8,075,914,2011
  118. ChristinaA.J. Circadian Rhythm of Blood Pressure and its Modulation by the Antihypertensive Drugs in Hypertensive Patients of South Tamilnadu.Doctoral dissertation, The Tamilnadu Dr. MGR Medical University, Chennai).
     [Google Scholar]
  119. TobeihaM. JafariA. FadaeiS. MirazimiS.M.A. DashtiF. AmiriA. KhanH. AsemiZ. ReiterR.J. HamblinM.R. MirzaeiH. Evidence for the benefits of melatonin in cardiovascular disease.Front. Cardiovasc. Med.2022988831910.3389/fcvm.2022.88831935795371
     [Google Scholar]
  120. KhosraviA. AndalibE. KhaledifarA. HajizadehM. NejatiM. BehjatiM. Pulmonary thromboembolism presenting with recurrent bradycardia and hypotension.Tanaffos201716324825029849680
     [Google Scholar]
  121. BodinF. Pharmaceutical composition for the treatment of Pulmonary arterial hypertension.Patent US 10/306,434,2004
  122. DesaiN.P. Soon-ShiongP. Methods and compositions for treating pulmonary hypertension.Patent US. 15/714:954,2018
  123. McMurrayJ.J.V. ÖstergrenJ. SwedbergK. GrangerC.B. HeldP. MichelsonE.L. OlofssonB. YusufS. PfefferM.A. CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial.Lancet2003362938676777110.1016/S0140‑6736(03)14283‑313678869
     [Google Scholar]
  124. GarauletM. QianJ. FlorezJ.C. ArendtJ. SaxenaR. ScheerF.A.J.L. Melatonin effects on glucose metabolism: Time to unlock the controversy.Trends Endocrinol. Metab.202031319220410.1016/j.tem.2019.11.01131901302
     [Google Scholar]
  125. FonkenL.K. NelsonR.J. The effects of light at night on circadian clocks and metabolism.Endocr. Rev.201435464867010.1210/er.2013‑105124673196
     [Google Scholar]
  126. KohyamaJ. A newly proposed disease condition produced by light exposure during night: Asynchronization.Brain Dev.200931425527310.1016/j.braindev.2008.07.00618757146
     [Google Scholar]
  127. PeschkeE. Melatonin, endocrine pancreas and diabetes.J. Pineal Res.2008441264010.1111/j.1600‑079X.2007.00519.x18078445
     [Google Scholar]
  128. SteigerA. Sleep and the hypothalamo–pituitary–adrenocortical system.Sleep Med. Rev.20026212513810.1053/smrv.2001.015912531148
     [Google Scholar]
  129. KempD.M. UbedaM. HabenerJ.F. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic β cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling.Mol. Cell. Endocrinol.2002191215716610.1016/S0303‑7207(02)00064‑312062899
     [Google Scholar]
  130. MurialdoG. CostelliP. FonziS. ParodiC. TorreF. CenacchiT. PollenA. Circadian secretion of melatonin and thyrotropin in hospitalized aged patients.Aging Clin. Exp. Res.199351394610.1007/BF033241258481424
     [Google Scholar]
  131. OhashiY. OkamotoN. UchidaK. IyoM. MoriN. MoritaY. Differential pattern of the circadian rhythm of serum melatonin in young and elderly healthy subjects.Neurosignals199764-630130610.1159/0001091419500669
     [Google Scholar]
  132. HardelandR. Investigational melatonin receptor agonists.Expert Opin. Investig. Drugs201019674776410.1517/13543784.2010.48292620408738
     [Google Scholar]
  133. Rahbari-OskouiF.F. AbramsonJ.L. BruckmanA.M. ChapmanA.B. CotsonisG.A. JohnsonS.A. BliwiseD.L. Nighttime administration of high-dose, sustained-release melatonin does not decrease nocturnal blood pressure in African-American patients: Results from a preliminary randomized, crossover trial.Complement. Ther. Med.20194315716410.1016/j.ctim.2019.01.02630935524
     [Google Scholar]
  134. Rufino-FelipeE. Colorado-PeraltaR. Reyes-MárquezV. ValdésH. Morales-MoralesD. Fluorinated-NHC transition metal complexes: Leading characters as potential anticancer metallodrugs.Anticancer. Agents Med. Chem.202121893894810.2174/187152062066620090810345232900353
     [Google Scholar]
  135. ShahN. AbdallaM.A. DeshmukhH. SathyapalanT. Therapeutics for type-2 diabetes mellitus: A glance at the recent inclusions and novel agents under development for use in clinical practice.Ther. Adv. Endocrinol. Metab.2021122042018821104214510.1177/2042018821104214534589201
     [Google Scholar]
  136. KennawayD.J. Melatonin research in mice: A review.Chronobiol. Int.20193691167118310.1080/07420528.2019.162437331198062
     [Google Scholar]
  137. MaidaA. HansotiaT. LonguetC. SeinoY. DruckerD.J. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.Gastroenterology200913762146215710.1053/j.gastro.2009.09.00419766644
     [Google Scholar]
  138. WatanabeT. KawabataK. WatanabeY. YuyamaH. MasudaN. BurgardE.C. Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed urinary incontinence, and method for screening compound comprised in said pharmaceutical composition.Patent US 14/413:948.,2015
  139. MichelM. Pharmaceutical composition for treating stress incontinence and/or mixed incontinence.Patent WO2005046666A1,2006
  140. Gomez-PinillaP.J. GomezM.F. SwärdK. HedlundP. HellstrandP. CamelloP.J. AnderssonK.E. PozoM.J. Melatonin restores impaired contractility in aged guinea pig urinary bladder.J. Pineal Res.200844441642510.1111/j.1600‑079X.2007.00544.x18194201
     [Google Scholar]
  141. AnderssonK.E. ArnerA. Urinary bladder contraction and relaxation: Physiology and pathophysiology.Physiol. Rev.200484393598610.1152/physrev.00038.200315269341
     [Google Scholar]
  142. Gomez-PinillaP.J. GomezM.F. HedlundP. SwärdK. HellstrandP. CamelloP.J. PozoM.J. AnderssonK.E. Effect of melatonin on age associated changes in Guinea pig bladder function.J. Urol.200717741558156110.1016/j.juro.2006.11.07117382778
     [Google Scholar]
  143. SánchezA.B. ClaresB. Rodríguez-LagunasM.J. FábregaM.J. CalpenaA.C. Study of melatonin as preventive agent of gastrointestinal damage induced by sodium diclofenac.Cells20209118010.3390/cells901018031936877
     [Google Scholar]
  144. TarnawskiA.S. AhluwaliaA. JonesM.K. The mechanisms of gastric mucosal injury: Focus on microvascular endothelium as a key target.Curr. Med. Chem.201219141510.2174/09298671280341407922300071
     [Google Scholar]
  145. TarnawskiA.S. AhluwaliaA. JonesM.K. Increased susceptibility of aging gastric mucosa to injury: The mechanisms and clinical implications.World J. Gastroenterol.201420164467448210.3748/wjg.v20.i16.446724782600
     [Google Scholar]
  146. MaQ. ReiterR.J. ChenY. Role of melatonin in controlling angiogenesis under physiological and pathological conditions.Angiogenesis20202329110410.1007/s10456‑019‑09689‑731650428
     [Google Scholar]
  147. MantleD. SmitsM.G. Melatonin for the treatment of gastrointestinal disorders: An overview.Gastrointest. Nurs.2021193182210.12968/gasn.2021.19.3.18
     [Google Scholar]
  148. WerbachM.R. Melatonin for the treatment of gastroesophageal reflux disease.Altern. Ther. Health Med.2008144545818616070
     [Google Scholar]
  149. PawlikM.W. KwiecienS. Ptak-BelowskaA. PajdoR. OlszaneckiR. SuskiM. MadejJ. TargoszA. KonturekS.J. KorbutR. BrzozowskiT. The renin-angiotensin system and its vasoactive metabolite angiotensin-(1-7) in the mechanism of the healing of preexisting gastric ulcers. The involvement of Mas receptors, nitric oxide, prostaglandins and proinflammatory cytokines.J. Physiol. Pharmacol.2016671759127010897
     [Google Scholar]
  150. PereiraR.S. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole.J. Pineal Res.200641319520010.1111/j.1600‑079X.2006.00359.x16948779
     [Google Scholar]
  151. MachowskaA. BrzozowskiT. SliwowskiZ. PawlikM. KonturekP.C. PajdoR. SzlachcicA. DrozdowiczD. SchwarzM. StachuraJ. KonturekS.J. PawlikW.W. Gastric secretion, proinflammatory cytokines and epidermal growth factor (EGF) in the delayed healing of lingual and gastric ulcerations by testosterone.Inflammopharmacology2008161404710.1007/s10787‑007‑1600‑618046513
     [Google Scholar]
  152. HollowayR.H. Systemic pharmacomodulation of transient lower esophageal sphincter relaxations11Reprints are not available.Am. J. Med.20011118Suppl. 8A17818510.1016/S0002‑9343(01)00853‑111749947
     [Google Scholar]
  153. ThomsonA.B.R. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole.Curr. Gastroenterol. Rep.20002648249310.1007/s11894‑000‑0013‑011079051
     [Google Scholar]
  154. CelinskiK. KonturekS.J. KonturekP.C. BrzozowskiT. Cichoz-LachH. SlomkaM. MalgorzataP. BielanskiW. ReiterR.J. Melatonin or l ‐tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole.J. Pineal Res.201150438939410.1111/j.1600‑079X.2011.00855.x21362032
     [Google Scholar]
  155. GittoE. PellegrinoS. GittoP. BarberiI. ReiterR.J. Oxidative stress of the newborn in the pre‐ and postnatal period and the clinical utility of melatonin.J. Pineal Res.200946212813910.1111/j.1600‑079X.2008.00649.x19054296
     [Google Scholar]
  156. van de WinkelA. MasslR. KuipersE.J. van der LaanL.J.W. PeppelenboschM.P. Digestive disease week 2011: highlights of clinical and preclinical research on Barrett’s esophagus and associated esophageal adenocarcinoma.Dis. Esophagus201326213014010.1111/j.1442‑2050.2012.01340.x22458661
     [Google Scholar]
  157. WangD.H. TiwariA. KimM.E. ZhangQ. SpechlerS.J. SouzaR.F. Esophageal squamous cell lines derived from GERD patients with and without Barrett’s esophagus differ markedly in their expression of SOX9 and columnar cytokeratins 8 and 18.Gastroenterology20111405S-75S-7610.1016/S0016‑5085(11)60304‑1
     [Google Scholar]
  158. ZanghiB.M. Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates.Patent US 8,492,331,2013
     [Google Scholar]
  159. SalehiB. SharopovF. FokouP. KobylinskaA. JongeL. TadioK. Sharifi-RadJ. PosmykM. MartorellM. MartinsN. IritiM. Melatonin in medicinal and food plants: Occurrence, bioavailability, and health potential for humans.Cells20198768110.3390/cells807068131284489
     [Google Scholar]
  160. Navarro-AlarcónM. Ruiz-OjedaF.J. Blanca-HerreraR.M. A-SerranoM.M. Acuña-CastroviejoD. Fernández-VázquezG. AgilA. Melatonin and metabolic regulation: A review.Food Funct.20145112806283210.1039/C4FO00317A25207999
     [Google Scholar]
  161. KorkmazA. TopalT. TanD.X. ReiterR.J. Role of melatonin in metabolic regulation.Rev. Endocr. Metab. Disord.200910426127010.1007/s11154‑009‑9117‑519911281
     [Google Scholar]
  162. DullooA.G. The search for compounds that stimulate thermogenesis in obesity management: From pharmaceuticals to functional food ingredients.Obes. Rev.2011121086688310.1111/j.1467‑789X.2011.00909.x21951333
     [Google Scholar]
  163. Montserrat-de la PazS. Pérez-PérezA. Vilariño-GarcíaT. Jiménez-CorteganaC. MurianaF.J.G. Millán-LinaresM.C. Sánchez-MargaletV. Nutritional modulation of leptin expression and leptin action in obesity and obesity-associated complications.J. Nutr. Biochem.20218910856110.1016/j.jnutbio.2020.10856133249183
     [Google Scholar]
  164. AlsayedM. El-KadyD.S. TantawyM.A. Novel melatonin derivatives: Synthesis, anticancer evaluations and molecular-docking study.Egypt. J. Chem.20216431517153310.21608/ejchem.2020.49430.3016
     [Google Scholar]
  165. RevialG. JabinI. LimS. PfauM. Aromatization of 1,6,7,7a-tetrahydro-2H-indol-2-ones by a novel process. Preparation of key-intermediate methyl 1-benzyl-5-methoxy-1H-indole-3-acetate and the syntheses of serotonin, melatonin, and bufotenin.J. Org. Chem.20026772252225610.1021/jo011059711925236
     [Google Scholar]
  166. SoniV. KhakeS.M. PunjiB. Nickel-catalyzed C (sp2)–H/C (sp3)–H oxidative coupling of indoles with toluene derivatives.ACS Catal.2017764202420810.1021/acscatal.7b01044
     [Google Scholar]
  167. KirschM. De GrootH. N ‐Nitrosomelatonin: Synthesis, chemical properties, potential prodrug.J. Pineal Res.200946212112710.1111/j.1600‑079X.2008.00655.x19141085
     [Google Scholar]
  168. TsotinisA. VlachouM. EleutheriadesA. PrineaE. EbreoD. TheM.T. SugdenD. Synthesis of N1-phenethyl substituted indole derivatives as new melatoninergic agonists and antagonists.Chem. Pharm. Bull.2002501313910.1248/cpb.50.3111824582
     [Google Scholar]
  169. SpadoniG. BalsaminiC. BediniA. DiamantiniG. Di GiacomoB. TontiniA. TarziaG. MorM. PlazziP.V. RivaraS. NonnoR. PannacciM. LuciniV. FraschiniF. StankovB.M. 2-[N-Acylamino(C1-C3)alkyl]indoles as MT1 melatonin receptor partial agonists, antagonists, and putative inverse agonists.J. Med. Chem.199841193624363410.1021/jm970721h9733487
     [Google Scholar]
  170. KoikeT. TakaiT. HoashiY. NakayamaM. KosugiY. NakashimaM. YoshikuboS. HiraiK. UchikawaO. Synthesis of a novel series of tricyclic dihydrofuran derivatives: Discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a]pyridines as melatonin receptor (MT1/MT2) ligands.J. Med. Chem.201154124207421810.1021/jm200385u21568291
     [Google Scholar]
  171. BahugunaA. KumarA. KumarS. ChhabraT. KrishnanV. 2D‐2D nanocomposite of MoS2‐graphitic carbon nitride as multifunctional catalyst for sustainable synthesis of C3‐functionalized indoles.ChemCatChem201810143121313210.1002/cctc.201800369
     [Google Scholar]
  172. ZafarW. SumrraS.H. HassanA.U. ChohanZ.H. A review on ‘sulfonamides’: Their chemistry and pharmacological potentials for designing therapeutic drugs in medical science.J. Coord. Chem.2023765-654658010.1080/00958972.2023.2208260
     [Google Scholar]
  173. ZafarW. AshfaqM. SumrraS.H. A review on the antimicrobial assessment of triazole-azomethine functionalized frameworks incorporating transition metals.J. Mol. Struct.2023128813574410.1016/j.molstruc.2023.135744
     [Google Scholar]
  174. MaraisW. HolzapfelC.W. On a facile synthesis of melatonin and other related indoles.Synth. Commun.199828193681369110.1080/00397919808004915
     [Google Scholar]
  175. PubChem Compound Summary for CID 1864, 6-Hydroxymelatonin.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/6-Hydroxymelatonin
  176. PubChem Substance Record for SID 103476522, CHEMBL199585.2004Available from: https://pubchem.ncbi.nlm.nih.gov/substance/103476522
  177. PubChem Compound Summary for CID 10220503, Tasimelteon.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Tasimelteon
  178. PubChem Compound Summary for CID 1858, 6-Chloromelatonin.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/6-Chloromelatonin
  179. PubChem Compound Summary for CID 644212, acetamide, N-[2-(2-iodo-5-methoxy-1H-indol-3-yl)ethyl]-2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/2-_125I_Iodomelatonin
  180. PubChem Compound Summary for CID 1785786, N-Acetyl-6-methoxytryptamine.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/N-Acetyl-6-methoxytryptamine
  181. Chem Compound Summary for CID 4018512, N-[2-(5-methoxy-2-phenyl-1H-indol-3-yl)ethyl]acetamide.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/2-phenylmelatonin
  182. PubChem Compound Summary for CID 86086004, n-(4-Chlorobenzoyl)-melatonin.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/n-_4-Chlorobenzoyl_-melatonin
  183. PubChem Compound Summary for CID 11599119, 7-[(6-chloro-1,2,3,4-tetrahydroacridin-9-yl)amino]-N-[2-(1H-indol-3-yl)ethyl]heptanamide.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/11599119
  184. PubChem Compound Summary for CID 608124, 3-(2-acetamidoethyl)-5-methoxy-1H-indole-2-carboxylic acid.2004Available from: https://pubchem.ncbi.nlm.nih.gov/compound/608124
  185. PubChem Substance Record for SID 103837832, 19819-92-2.2004Available from: https://pubchem.ncbi.nlm.nih.gov/substance/103837832
/content/journals/ctmc/10.2174/0115680266331681250130072302
Loading
Progress in Synthetic Approaches and Pharmacological Applications of Melatonin and Its Derivatives: A Comprehensive Review
Curr. Top. Med. Chem. 25, 2215 (2025); https://doi.org/10.2174/0115680266331681250130072302
/content/journals/ctmc/10.2174/0115680266331681250130072302
/content/journals/ctmc/10.2174/0115680266331681250130072302
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): biological activity; cancer; circadian rhythm; CNS activity; GI tract; hypertension; insomnia; Melatonin; skin; tissue healing

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test